MRSAid | Ondine Biomedical

By: Ondine Biomedical  09-12-2011
Keywords: Antibiotics, Mrsa

About MRSAid™

The MRSAid™ system was developed by Ondine Biomedical with the goal of safe, rapid, and complete eradication of bacterial pathogens from the nasal passages. During treatment the photosensitizer formulation is gently applied to the nasal openings, after which a painless illumination step completes the process. The treatment only lasts a few minutes and does not require any non-standard patient preparation. The proprietary photosensitizer formulation developed for MRSAid™ was designed to achieve high levels of immediate bactericidal activity while also providing a sustained effect to prevent rebound/regrowth of pathogens after treatment.

Preclinical results testing the MRSAid™ system for safety and efficacy have been peer-reviewed and presented at international conferences in the areas of photodynamics and infection control. Early in vitro studies demonstrated that the system is 100% effective in eradication of both S. aureus and MRSA under optimized photosensitizer and energy dose conditions. Subsequent testing using epithelialized human skin cultures demonstrated the ability to eliminate established topical colonization of MRSA with a single 4 minute treatment. In addition, morphological assessment of treated skin samples showed that treatment with MRSAid™ did not induce tissue damage. Finally, another study showed that resistance to aPDT could not be induced in strains of S. aureus or MRSA with repeated sub-lethal exposures. In contrast, complete resistance to antibiotics could be achieved using a similar exposure model.

Human testing using MRSAid™ for nasal decolonization has taken place in Canada and Europe. Evaluations in Germany using several treatment protocols showed complete elimination of nasal MRSA carriage in 17 of 19 subjects. Subsequent testing in a Canadian MRSA clinic also showed that complete nasal eradication could be achieved with a single application of MRSAid™ and decolonization was maintained over multiple days post-treatment. These promising results have supported the design of two major clinical studies to be performed at key infection control centers in Canada.

The MRSAid™ Advantage

Current MRSA decolonization procedures vary widely, but usually consist of some combination of disinfectant body wash, topical antibiotic for nasal clearance (e.g. mupirocin), and systemic antibiotic therapy. While these methods can be effective, the widespread use of antibiotics is associated with a growing incidence of resistance. Furthermore, topical antibiotics require a treatment course of 5 or more days to be effective, raising issues of patient compliance and potential communicability over the course of therapy. The MRSAid™ system is designed to work as part of a broad infection control/decolonization protocol. It may be used adjunctively with or in replacement of topical nasal antibiotics, and offers the distinct advantages of: 1) absence of development of bacterial resistance to the killing mechanism of aPDT, 2) elimination of patient compliance issues with a multi-day treatment schedule, and 3) immediate and powerful nasal decolonization of pathogens. For these reasons, MRSAid™ is expected to become a valuable tool to fight infections in the healthcare setting.

Product Development Status

This system has been approved as a medical device for use and sale in Canada and is pending approval in the European Union.

Keywords: Antibiotics, Mrsa

Contact Ondine Biomedical

Email - none provided

Print this page

Other products and services from Ondine Biomedical


Vitalwave | Ondine Biomedical

A charitable group known (Courthill Foundation) contracts Ondine Biomedical Corporation for the development of this potentially life saving application. Vitalwave™ is a treatment designed to decolonize the birth canal in the hopes of preventing vertical transmission of HIV and other pathogens. Vitalwave™ has undergone development to the prototype stage, and is expected to be beta tested in the near future.


Endowave (VAP) | Ondine Biomedical

Ondine believes that reducing the microbial load in ETT’s will result in reduced ventilator associated pneumonia infection rate, less reliance on antibiotics and reduced average length of hospital stay for intubated patients. Endowave™ is the first treatment using photodisinfection to eradicate bacterial biofilms on the inner surface of endotracheal tubes, thus preventing the aspiration of pathogens in a mechanically ventilated patient.


Periowave | Ondine Biomedical

Periowave™ uses the powerful photodisinfection reaction to inactivate the bacteria and toxins that are left behind after scaling and root planing.First, a small quantity of blue-coloured photosensitizer solution is topically applied to the gums at the treatment site where it attaches to microbes and toxins associated with gum disease.


Sinuwave | Ondine Biomedical

Chronic Sinusitis patients visit their primary physicians twice as often as those without the disorder, and have 5 times as many prescriptions filled. This product is in the early stages of development, including in vitro testing at Ondine Research Labs. More than half of all Chronic Sinusitis outpatient visits result in prescription medication. Chronic Sinusitis patients make 15 million visits to outpatient clinics.